MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER

For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets
Médium: Artigo
Jazyk:Russo
Vydáno: QUASAR, LLC 2018-03-01
Edice:Issledovaniâ i Praktika v Medicine
Témata:
bladder cancer
pd-1
pd-l1
immunotherapy
atezolizumab
nivolumab
pembrolizumab
avelumab
durvalumab
On-line přístup:https://www.rpmj.ru/rpmj/article/view/246
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky